Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edgar Jost

Showing results (101-110 of 108) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 108 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2024
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance LeukemiaChristoph Röllig, Björn Steffen, Christoph Schliemann, et al.
American Journal of Hematology|January 6, 2026
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction TherapyStefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer, et al.
Journal of Hematology & Oncology|September 5, 2022
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantationDesiree Kunadt, Sebastian Stasik, Klaus H Metzeler, et al.
Haematologica|May 28, 2021
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative studySabine Kayser, Richard F Schlenk, Delphine Lebon, et al.
Blood Advances|November 6, 2024
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemiaLeo Ruhnke, Marius Bill, Sven Zukunft, et al.
Haematologica|June 9, 2022
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4Sabine Kayser, David Martínez-Cuadrón, Maher Hanoun, et al.
Leukemia|July 21, 2025
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysisJulian Ronnacker, Philippe J Muller, Jan-Henrik Mikesch, et al.
Blood|April 14, 2026
Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidationEnise Ceran, Sonia Jaramillo, Anne Kathrin Merbach, et al.
Pageof 11

Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2024
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance LeukemiaChristoph Röllig, Björn Steffen, Christoph Schliemann, et al.
American Journal of Hematology|January 6, 2026
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction TherapyStefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer, et al.
Journal of Hematology & Oncology|September 5, 2022
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantationDesiree Kunadt, Sebastian Stasik, Klaus H Metzeler, et al.
Haematologica|May 28, 2021
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative studySabine Kayser, Richard F Schlenk, Delphine Lebon, et al.
Blood Advances|November 6, 2024
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemiaLeo Ruhnke, Marius Bill, Sven Zukunft, et al.
Haematologica|June 9, 2022
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4Sabine Kayser, David Martínez-Cuadrón, Maher Hanoun, et al.
Leukemia|July 21, 2025
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysisJulian Ronnacker, Philippe J Muller, Jan-Henrik Mikesch, et al.
Blood|April 14, 2026
Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidationEnise Ceran, Sonia Jaramillo, Anne Kathrin Merbach, et al.
Pageof 11